1. A method of treating a subject suffering from cancer lacking NMT2, comprising administering to said subject an N-myristoyltransferase (NMT) inhibitor. The method of claim 1, wherein said NMT inhibitor is an NMT1.3 inhibitor. The method of claim 2, wherein said cancer is lymphoma. The method of claim 3, wherein said lymphoma is a B-cell lymphoma. The method of claim 4, wherein said B-cell lymphoma is follicular lymphoma, diffuse large-cell B-cell lymphoma, mantle cell lymphoma, chronic B-cell lymphocytic leukemia (B-CLL) / small-cell lymphocytic lymphoma (SLL), immunocytoma / Waldenstrom disease, extranodal B-cell lymphoma from marginal zone cells (MALT-type lymphoma) / monocytoid B-cell lymphoma, Burkitt's lymphoma, childhood lymphoma or anaplastic large cell lymphoma. 6. The method of claim 2, wherein said NMT inhibitor is a small molecule, an antibody, a peptide fragment, or a nucleic acid. The method of claim 6, wherein said small molecule is Tris (dibenzylideneacetone) dipalladium (Tris-DBA), 2-hydroxymyristate (MMC), DDD85646 or a derivative thereof. The method of claim 6, wherein said antibody is a monoclonal antibody or a polyclonal antibody. The method of claim 6, wherein said nucleic acid comprises a dsRNA molecule, an mRNA molecule, a miRNA molecule, a ribozyme, a kshRNA molecule, or an siRNA molecule. The method of claim 1, wherein said subject is a human. The method of claim 1, further comprising administering a chemotherapeutic agent. The method of claim 11, wherein said chemotherapeutic agent1. Способ лечения субъекта, страдающего раком, лишенным NMT2, включающий введение упомянутому субъекту ингибитора N-миристоилтрансферазы (NMT).2. Способ по п. 1, где упомянутый ингибитор NMT представляет собой ингибитор NMT1.3. Способ по п. 2, где упомянутый рак представляет собой лимфому.4. Способ по п. 3. где упомянутая лимфома представляет собой В-клеточную лимфому.5. Способ по п. 4, где упомянутая В-клеточная лимфома представляет собой фолликулярную лимфому,
